The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease
- 19 November 2010
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Neuroscience
- Vol. 11 (12), 791-797
- https://doi.org/10.1038/nrn2935
Abstract
No abstract availableKeywords
This publication has 74 references indexed in Scilit:
- α-Synuclein Promotes SNARE-Complex Assembly in Vivo and in VitroScience, 2010
- Expression, purification and preliminary biochemical studies of the N-terminal domain of leucine-rich repeat kinase 2Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2010
- Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's diseaseNature Medicine, 2010
- Enhanced Striatal Dopamine Transmission and Motor Performance with LRRK2 Overexpression in Mice Is Eliminated by Familial Parkinson's Disease Mutation G2019SJournal of Neuroscience, 2010
- Mutant LRRK2R1441G BAC transgenic mice recapitulate cardinal features of Parkinson's diseaseNature Neuroscience, 2009
- α-Synuclein and neuronal cell deathMolecular Neurodegeneration, 2009
- Leucine-Rich Repeat Kinase 2 Mutations and Parkinson's Disease: Three QuestionsASN Neuro, 2009
- Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in DrosophilaThe EMBO Journal, 2008
- Role of autophagy in G2019S‐LRRK2‐associated neurite shortening in differentiated SH‐SY5Y cellsJournal of Neurochemistry, 2008
- The R1441C mutation of LRRK2 disrupts GTP hydrolysisBiochemical and Biophysical Research Communications, 2007